Treatments and Therapies | Alzheimer's Society

What is lecanemab?

Lecanemab, also known as Leqembi, has made headlines as the first drug ever approved in the UK by the MHRA that can slow down early-stage Alzheimer’s disease, but it has not been recommended for use in the NHS at this stage. Here is what we know so far.

Research

Three promising drugs for treating Alzheimer's disease bring fresh hope

22 August 2024

Real stories

Reminiscence therapy helped my mum with dementia return to her roots

24 October 2023

Alzheimer's Society respond to FDA decision on Alzheimer's drug lecanemab

The Food and Drug Administration has today approved lecanemab, a new drug for Alzheimer's disease, for use across the US.

Alzheimer's Society comment on disappointing results for gantenerumab drug at clinical trial

Alzheimer's Society, study participant Eric Deeson and Sir Prof John Hardy comment on the disappointing clinical trial results for Alzheimer's drug gantenerumab.

Alzheimer's Society comment on today's 'breakthrough' Alzheimer's drug news

Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, comments on news surrounding breakthrough Alzheimer's drug lecanemab.

Progress with new Alzheimer’s drug lecanemab announced by manufacturers Eisai and Biogen

Yesterday (27 September 2022), Eisai Co. Ltd. and Biogen announced top-line results for a major trial on the drug lecanemab in slowing down the progress of Alzheimer’s disease. Alzheimer's Society comments on this Alzheimer’s progression drug hope.

Research

What is Aducanumab and what could this dementia drug mean for people with Alzheimer's disease?

22 December 2021

Alzheimer's Society responds to EMA rejection of aducanumab

The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. The drug was previously approved for use in the US by the Food and Drug Administration (FDA) on 7 June 2021.

Real stories

Art therapy helps my grandmother with her dementia and my autism

20 September 2021

Helping the brain’s ‘waste disposal’

From the spring 2016 edition of Care and cure magazine, a new study shows that a drug originally developed as an antidepressant may work to enhance the brain's 'waste disposal' and slow the progress of Alzheimer's disease.

Immune system retargeted to remove toxic protein

From the Summer 2016 edition of Care and cure magazine, injections of an immune system protein can trigger the fight against the signs of Alzheimer's disease in mice.

Investigating how to clear toxic amyloid protein from the brain in Alzheimer’s disease

Research project: Understanding the molecular basis of Amyloid beta peptide interaction by neprilysin in Alzheimer’s disease.